A randomized, double-blind, Phase 2, dose-finding trial of once weekly petrelintide compared with placebo in participants with obesity or overweight with weight related comorbidities

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512549-18-00

Acronym

ZP8396-23094

Enrollment

220

Registered

2024-12-16

Start date

2024-12-19

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weight management

Brief summary

Change in body weight (%) from baseline to week 28

Detailed description

Body weight loss of ≥5% from baseline to week 28 (Y/N), Body weight loss of ≥10% from baseline to week 28 (Y/N)

Interventions

DRUGPlacebo for petrelintide

DRUGPetrelintide

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in body weight (%) from baseline to week 28	—

Secondary

Measure	Time frame
Body weight loss of ≥5% from baseline to week 28 (Y/N), Body weight loss of ≥10% from baseline to week 28 (Y/N)	—

Countries

Poland, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026